Refine by
Endovascular Articles & Analysis
99 news found
“The CE Mark represents a major step forward in enhancing patient care and safety for endovascular therapies in the EU, a market with a higher prevalence of PE when compared to the United States,” said Laura Piccinini, AngioDynamics Senior Vice President/General Manager, Endovascular Therapies and International. ...
Many therapies are now available, including intraperitoneal chemotherapy, topical chemotherapy, endovascular embolization, and therapeutic radiation. Along with these traditional treatments, more research is also being conducted into immunotherapy and gene therapy techniques that hold great promise in providing new treatments for cancer. ...
TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a ...
” “The FLASH registry data presented in the Late-Breaking Clinical Trials session at TCT represents the largest study to date in the interventional approach to PE, which is the 3rd leading cause of cardiovascular death,” said Dr. Sahil Parikh, Director of Endovascular Services at Columbia University Irving Medical Center and Associate Professor of Medicine at ...
” The ModulHeart device provides hemodynamic support through three endovascular pumps inserted in series and assembled in parallel into a self-expandable anchor implanted in the descending aorta. ...
GLP Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular Space HINGHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. ...
Flacke is a proven innovator in the robotics field and has pioneered new solutions for his patients in interventional radiology, specifically the endovascular space,” commented Harel Gadot, Chairman, CEO, and President. ...
The comprehensive trial, which is anticipated to commence later this month, will be performed by a team of global leaders in the endovascular space at a state-of-the-art lab with FDA approved levels of planning, controlling, monitoring and reporting (GLP standards). ...
(NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced three new data sets will be presented during Late-Breaking Clinical Trial sessions at the 2022 TCT (Transcatheter Cardiovascular Therapeutics) and the 2022 VEINS (Venous Endovascular ...
Confluent partners with leading OEMs to create a selective product portfolio which includes such complex applications as transcatheter heart valves, neurovascular implants, endovascular stent grafts, and advanced smart catheters. With facilities in Fremont and Laguna Niguel, California; Warwick, Rhode Island; Windham, Maine; Austin, Texas; Chattanooga, Tennessee; and San Jose, ...
Today, MicroPort® is focused in covering ten major areas, including Cardiovascular Intervention & Structural Heart Diseases, Electrophysiology & Cardiac Rhythm Management, Orthopedics & Soft Tissue Repair, Endovascular & Peripheral Vascular Diseases, Neurovascular Intervention & Neurosciences, Life Sciences (Endocrine Management), Surgical Devices & ...
ByRobocath
Synchron, an endovascular brain-computer interface (BCI) company, today announced the first human BCI implant in the United States. This procedure represents a significant technological milestone for scalable BCI devices and is the first to occur in the U.S. using an endovascular BCI approach, which does not require invasive open-brain surgery. ...
Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. ...
Saranas Inc., a medical device company pioneering technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced that it has been named one of Houston’s most innovative companies. ...
Saranas, Inc., developer of the Early Bird® Bleed Monitoring System designed for early detection of internal bleed complications during endovascular procedures, has been awarded a group purchasing agreement with Premier Inc., as part of Premier’s Technology Breakthroughs program. ...
SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac/endovascular ...
“Prior to the PAD III study, there were limited long-term data available to provide treatment guidance for this challenging population since patients with severe calcification have historically been excluded from endovascular trials,” said William A. Gray, M.D., FACC, FSCAI, Co-Director of the Lankenau Heart Institute and System, Chief of the Division of ...
Team Gleason and Synchron, an endovascular brain computer interface company, today announced a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities like ALS, muscular dystrophy, and cerebral palsy. ...
Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients with severe paralysis, at Mount Sinai Hospital in New York. ...
Schermerhorn, Chief, Division of Vascular and Endovascular Surgery at Beth Israel Deaconess Medical Center. “The decision regarding which patients to treat with TCAR is no longer restricted to patients at high surgical risk, providing a greater opportunity for the care-team to pursue the less invasive approach for a broader set of their patients. ...